NexImmune (STU:7370) ROE % Adjusted to Book Value: -65.09% (As of Jun. 2024)


STU:7370 NexImmune Inc STU:7370
33 GF Score
Price €4.55
View Full Analysis

What is NexImmune ROE % Adjusted to Book Value?

NexImmune STU:7370 33 ROE % Adjusted to Book Value is -65.09% as of Jun. 2024. GuruFocus rates STU:7370 with a GF Score™ of 33/100.

NexImmune's ROE % for the quarter that ended in Jun. 2024 was -482.32%. NexImmune's PB Ratio for the quarter that ended in Jun. 2024 was 7.41. NexImmune's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was -65.09%.

NexImmune ROE % Adjusted to Book Value Related Terms

NexImmune ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for NexImmune's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexImmune ROE % Adjusted to Book Value Chart

NexImmune Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 0.00 -117.82 -663.53 -116.54

NexImmune Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -361.32 -500.46 -237.70 -166.24 -65.09

STU:7370 vs PPCBD, ENDV, XSNX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, NexImmune's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NexImmune ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NexImmune's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where NexImmune's ROE % Adjusted to Book Value falls into.


STU:7370
33GF Score
NexImmune Inc STU:7370
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NexImmune ROE % Adjusted to Book Value Calculation

NexImmune's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-175.97% / 1.51
=-116.54%

NexImmune's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-482.32% / 7.41
=-65.09%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -65.09% mean?
NexImmune (STU:7370) has a ROE % Adjusted to Book Value of -65.09% as of Jun. 2024. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on NexImmune and its competitors.
Is NexImmune's ROE % Adjusted to Book Value too high?
NexImmune's current ROE % Adjusted to Book Value is -65.09%. Overall, NexImmune has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does NexImmune's ROE % Adjusted to Book Value compare to PPCBD and ENDV?
NexImmune's ROE % Adjusted to Book Value of -65.09% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on NexImmune and its competitors. NexImmune's current ROE % Adjusted to Book Value is -65.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexImmune stock overvalued right now?
NexImmune (STU:7370) has a current ROE % Adjusted to Book Value of -65.09%. The current ROE % Adjusted to Book Value is -65.09%. NexImmune's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For NexImmune (STU:7370), the current ROE % Adjusted to Book Value is -65.09% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NexImmune Business Description

Address 9119 Gaither Road, Gaithersburg, MD, USA, 20877
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
33GF Score

Get the complete analysis for STU:7370

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.55
Price